TY  - JOUR
AU  - Mitropoulou, Christina
AU  - Fragoulakis, Vasilios
AU  - Rakićević, Ljiljana
AU  - Novković, Mirjana
AU  - Vozikis, Athanassios
AU  - Matić, Dragan M.
AU  - Antonijević, Nebojša
AU  - Radojković, Dragica 
AU  - van Schaik, Ron H.
AU  - Patrinos, George P.
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/965
AB  - Introduction: Clopidogrel, which is activated by the CYP2C19 enzyme, is among the drugs for which all major regulatory agencies recommend genetic testing to be performed to identify a patient's CYP2C19 genotype in order to determine the optimal antiplatelet therapeutic scheme. The CYP2C19*2 and CYP2C19*3 variants are loss-of-function alleles, leading to abolished CYP2C19 function and thus have the risk of thrombotic events for carriers of these alleles on standard dosages, while the CYP2C19*17 allele results in CYP2C19 hyperactivity. Aims: Here, we report our findings from a retrospective study to assess whether genotyping for the CYP2C19*2 allele was cost effective for myocardial infarction patients receiving clopidogrel treatment in the Serbian population compared with the nongenotype-guided treatment. Results: We found that 59.3% of the CYP2C19*1/*1 patients had a minor or major bleeding event versus 42.85% of the CYP2C19*1/*2 and *2/*2, while a reinfarction event occurred only in 2.3% of the CYP21C9*1/*1 patients, compared with 11.2% of the CYP2C19*1/*2 and CYP2C19*2/*2 patients. There were subtle differences between the two patient groups, as far as the duration of hospitalization and rehabilitation is concerned, in favor of the CYP2C19*1/*1 group. The mean cost for the CYP2C19*1/*1 patients was estimated at (sic)2547 versus (sic)2799 in the CYP2C19*1/*2 and CYP2C19*2/*2 patients. Furthermore, based on the overall CYP2C19*1/*2 genotype frequencies in the Serbian population, a break-even point analysis indicated that performing the genetic test prior to drug prescription represents a cost-saving option, saving (sic)13 per person on average. Conclusion: Overall, our data demonstrate that pharmacogenomics-guided clopidogrel treatment may represent a cost-saving approach for the management of myocardial infarction patients undergoing primary percutaneous coronary intervention in Serbia.
PB  - Future Medicine Ltd, London
T2  - Pharmacogenomics
T1  - Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention
EP  - 1784
IS  - 16
SP  - 1775
VL  - 17
DO  - 10.2217/pgs-2016-0052
ER  - 

@article{
author = "Mitropoulou, Christina and Fragoulakis, Vasilios and Rakićević, Ljiljana and Novković, Mirjana and Vozikis, Athanassios and Matić, Dragan M. and Antonijević, Nebojša and Radojković, Dragica  and van Schaik, Ron H. and Patrinos, George P.",
year = "2016",
abstract = "Introduction: Clopidogrel, which is activated by the CYP2C19 enzyme, is among the drugs for which all major regulatory agencies recommend genetic testing to be performed to identify a patient's CYP2C19 genotype in order to determine the optimal antiplatelet therapeutic scheme. The CYP2C19*2 and CYP2C19*3 variants are loss-of-function alleles, leading to abolished CYP2C19 function and thus have the risk of thrombotic events for carriers of these alleles on standard dosages, while the CYP2C19*17 allele results in CYP2C19 hyperactivity. Aims: Here, we report our findings from a retrospective study to assess whether genotyping for the CYP2C19*2 allele was cost effective for myocardial infarction patients receiving clopidogrel treatment in the Serbian population compared with the nongenotype-guided treatment. Results: We found that 59.3% of the CYP2C19*1/*1 patients had a minor or major bleeding event versus 42.85% of the CYP2C19*1/*2 and *2/*2, while a reinfarction event occurred only in 2.3% of the CYP21C9*1/*1 patients, compared with 11.2% of the CYP2C19*1/*2 and CYP2C19*2/*2 patients. There were subtle differences between the two patient groups, as far as the duration of hospitalization and rehabilitation is concerned, in favor of the CYP2C19*1/*1 group. The mean cost for the CYP2C19*1/*1 patients was estimated at (sic)2547 versus (sic)2799 in the CYP2C19*1/*2 and CYP2C19*2/*2 patients. Furthermore, based on the overall CYP2C19*1/*2 genotype frequencies in the Serbian population, a break-even point analysis indicated that performing the genetic test prior to drug prescription represents a cost-saving option, saving (sic)13 per person on average. Conclusion: Overall, our data demonstrate that pharmacogenomics-guided clopidogrel treatment may represent a cost-saving approach for the management of myocardial infarction patients undergoing primary percutaneous coronary intervention in Serbia.",
publisher = "Future Medicine Ltd, London",
journal = "Pharmacogenomics",
title = "Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention",
pages = "1784-1775",
number = "16",
volume = "17",
doi = "10.2217/pgs-2016-0052"
}

Mitropoulou, C., Fragoulakis, V., Rakićević, L., Novković, M., Vozikis, A., Matić, D. M., Antonijević, N., Radojković, D., van Schaik, R. H.,& Patrinos, G. P.. (2016). Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. in Pharmacogenomics
Future Medicine Ltd, London., 17(16), 1775-1784.
https://doi.org/10.2217/pgs-2016-0052

Mitropoulou C, Fragoulakis V, Rakićević L, Novković M, Vozikis A, Matić DM, Antonijević N, Radojković D, van Schaik RH, Patrinos GP. Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. in Pharmacogenomics. 2016;17(16):1775-1784.
doi:10.2217/pgs-2016-0052 .

Mitropoulou, Christina, Fragoulakis, Vasilios, Rakićević, Ljiljana, Novković, Mirjana, Vozikis, Athanassios, Matić, Dragan M., Antonijević, Nebojša, Radojković, Dragica , van Schaik, Ron H., Patrinos, George P., "Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention" in Pharmacogenomics, 17, no. 16 (2016):1775-1784,
https://doi.org/10.2217/pgs-2016-0052 . .

TY  - JOUR
AU  - Mizzi, Clint
AU  - Dalabira, Eleni
AU  - Kumuthini, Judit
AU  - Dzimiri, Nduna
AU  - Balogh, Istvan
AU  - Basak, Nazli
AU  - Boehm, Ruwen
AU  - Borg, Joseph
AU  - Borgiani, Paola
AU  - Bozina, Nada
AU  - Bruckmueller, Henrike
AU  - Burzynska, Beata
AU  - Carracedo, Angel
AU  - Cascorbi, Ingolf
AU  - Deltas, Constantinos
AU  - Dolzan, Vita
AU  - Fenech, Anthony
AU  - Grech, Godfrey
AU  - Kasiulevicius, Vytautas
AU  - Kadasi, L'udevit
AU  - Kucinskas, Vaidutis
AU  - Khusnutdinova, Elza
AU  - Loukas, Yiannis L.
AU  - Macek, Milan, Jr.
AU  - Makukh, Halyna
AU  - Mathijssen, Ron
AU  - Mitropoulos, Konstantinos
AU  - Mitropoulou, Christina
AU  - Novelli, Giuseppe
AU  - Papantoni, Ioanna
AU  - Pavlović, Sonja
AU  - Saglio, Giuseppe
AU  - Setrić, Jadranka
AU  - Stojiljković, Maja
AU  - Stubbs, Andrew P.
AU  - Squassina, Alessio
AU  - Torres, Maria
AU  - Turnovec, Marek
AU  - van Schaik, Ron H.
AU  - Voskarides, Konstantinos
AU  - Wakil, Salma M.
AU  - Werk, Anneke
AU  - del Zompo, Maria
AU  - Zukić, Branka
AU  - Katsila, Theodora
AU  - Lee, Ming Ta Michael
AU  - Motsinger-Rief, Alison
AU  - Mc Leod, Howard L.
AU  - van der Spek, Peter J.
AU  - Patrinos, George P.
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/909
AB  - Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant interpopulation pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable pharmacogenomic biomarkers in 7 European populations, affecting drug efficacy and/ or toxicity of 51 medication treatment modalities. These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned. Also, our data demonstrate notable differences in predicted genotype-based warfarin dosing among these populations. Our findings can be exploited not only to develop guidelines for medical prioritization, but most importantly to facilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomic testing. This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective.
PB  - Public Library Science, San Francisco
T2  - PLoS One
T1  - A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics
IS  - 9
VL  - 11
DO  - 10.1371/journal.pone.0162866
ER  - 

@article{
author = "Mizzi, Clint and Dalabira, Eleni and Kumuthini, Judit and Dzimiri, Nduna and Balogh, Istvan and Basak, Nazli and Boehm, Ruwen and Borg, Joseph and Borgiani, Paola and Bozina, Nada and Bruckmueller, Henrike and Burzynska, Beata and Carracedo, Angel and Cascorbi, Ingolf and Deltas, Constantinos and Dolzan, Vita and Fenech, Anthony and Grech, Godfrey and Kasiulevicius, Vytautas and Kadasi, L'udevit and Kucinskas, Vaidutis and Khusnutdinova, Elza and Loukas, Yiannis L. and Macek, Milan, Jr. and Makukh, Halyna and Mathijssen, Ron and Mitropoulos, Konstantinos and Mitropoulou, Christina and Novelli, Giuseppe and Papantoni, Ioanna and Pavlović, Sonja and Saglio, Giuseppe and Setrić, Jadranka and Stojiljković, Maja and Stubbs, Andrew P. and Squassina, Alessio and Torres, Maria and Turnovec, Marek and van Schaik, Ron H. and Voskarides, Konstantinos and Wakil, Salma M. and Werk, Anneke and del Zompo, Maria and Zukić, Branka and Katsila, Theodora and Lee, Ming Ta Michael and Motsinger-Rief, Alison and Mc Leod, Howard L. and van der Spek, Peter J. and Patrinos, George P.",
year = "2016",
abstract = "Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant interpopulation pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable pharmacogenomic biomarkers in 7 European populations, affecting drug efficacy and/ or toxicity of 51 medication treatment modalities. These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned. Also, our data demonstrate notable differences in predicted genotype-based warfarin dosing among these populations. Our findings can be exploited not only to develop guidelines for medical prioritization, but most importantly to facilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomic testing. This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective.",
publisher = "Public Library Science, San Francisco",
journal = "PLoS One",
title = "A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics",
number = "9",
volume = "11",
doi = "10.1371/journal.pone.0162866"
}

Mizzi, C., Dalabira, E., Kumuthini, J., Dzimiri, N., Balogh, I., Basak, N., Boehm, R., Borg, J., Borgiani, P., Bozina, N., Bruckmueller, H., Burzynska, B., Carracedo, A., Cascorbi, I., Deltas, C., Dolzan, V., Fenech, A., Grech, G., Kasiulevicius, V., Kadasi, L., Kucinskas, V., Khusnutdinova, E., Loukas, Y. L., Macek, M. Jr., Makukh, H., Mathijssen, R., Mitropoulos, K., Mitropoulou, C., Novelli, G., Papantoni, I., Pavlović, S., Saglio, G., Setrić, J., Stojiljković, M., Stubbs, A. P., Squassina, A., Torres, M., Turnovec, M., van Schaik, R. H., Voskarides, K., Wakil, S. M., Werk, A., del Zompo, M., Zukić, B., Katsila, T., Lee, M. T. M., Motsinger-Rief, A., Mc Leod, H. L., van der Spek, P. J.,& Patrinos, G. P.. (2016). A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. in PLoS One
Public Library Science, San Francisco., 11(9).
https://doi.org/10.1371/journal.pone.0162866

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Basak N, Boehm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kadasi L, Kucinskas V, Khusnutdinova E, Loukas YL, Macek MJ, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlović S, Saglio G, Setrić J, Stojiljković M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, del Zompo M, Zukić B, Katsila T, Lee MTM, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. in PLoS One. 2016;11(9).
doi:10.1371/journal.pone.0162866 .

Mizzi, Clint, Dalabira, Eleni, Kumuthini, Judit, Dzimiri, Nduna, Balogh, Istvan, Basak, Nazli, Boehm, Ruwen, Borg, Joseph, Borgiani, Paola, Bozina, Nada, Bruckmueller, Henrike, Burzynska, Beata, Carracedo, Angel, Cascorbi, Ingolf, Deltas, Constantinos, Dolzan, Vita, Fenech, Anthony, Grech, Godfrey, Kasiulevicius, Vytautas, Kadasi, L'udevit, Kucinskas, Vaidutis, Khusnutdinova, Elza, Loukas, Yiannis L., Macek, Milan, Jr., Makukh, Halyna, Mathijssen, Ron, Mitropoulos, Konstantinos, Mitropoulou, Christina, Novelli, Giuseppe, Papantoni, Ioanna, Pavlović, Sonja, Saglio, Giuseppe, Setrić, Jadranka, Stojiljković, Maja, Stubbs, Andrew P., Squassina, Alessio, Torres, Maria, Turnovec, Marek, van Schaik, Ron H., Voskarides, Konstantinos, Wakil, Salma M., Werk, Anneke, del Zompo, Maria, Zukić, Branka, Katsila, Theodora, Lee, Ming Ta Michael, Motsinger-Rief, Alison, Mc Leod, Howard L., van der Spek, Peter J., Patrinos, George P., "A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics" in PLoS One, 11, no. 9 (2016),
https://doi.org/10.1371/journal.pone.0162866 . .